Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers

Hanna M Romanska, Piotr Potemski, Magdalena Krakowska, Magdalena Mieszkowska, Shalini Chaudhri, Radzisław Kordek, Robert Kubiak, Valerie Speirs, Andrew M Hanby, Rafał Sadej, Fedor Berditchevski

Research output: Contribution to journalArticle

11 Citations (Scopus)
4 Downloads (Pure)

Abstract

BACKGROUND: The proposed involvement of CD151 in breast cancer (BCa) progression is based on findings from studies in invasive ductal carcinoma (IDC). The IDC and invasive lobular carcinoma (ILC) represent distinct disease entities. Here we evaluated clinical significance of CD151 alone and in association with integrin α3β1 in patients with ILC in context of the data of our recent IDC study.

METHODS: Expression of CD151 and/or integrin α3β1 was evaluated in ILC samples (N=117) using immunohistochemistry. The findings were analysed in relation to our results from an IDC cohort (N=182) demonstrating a prognostic value of an expression of CD151/integrin α3β1 complex in patients with HER2-negative tumours.

RESULTS: Unlike in the IDCs, neither CD151 nor CD151/α3β1 complex showed any correlation with any of the ILC characteristics. Lack of both CD151 and α3β1 was significantly correlated with poor survival (P=0.034) in lymph node-negative ILC N(-) cases. The CD151(-)/α3β1(-) patients had 3.12-fold higher risk of death from BCa in comparison with the rest of the ILC N(-) patients.

CONCLUSIONS: Biological role of CD151/α3β1 varies between ILC and IDC. Assessment of CD151/α3β1 might help to identify ILC N(-) patients with increased risk of distant metastases.

Original languageEnglish
Pages (from-to)1350-1357
Number of pages8
JournalBritish Journal of Cancer
Volume113
Issue number9
DOIs
Publication statusPublished - 3 Nov 2015

Fingerprint

Lobular Carcinoma
Integrins
Ductal Carcinoma
Breast Neoplasms
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis
Survival

Keywords

  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Carcinoma, Lobular
  • Female
  • Humans
  • Immunohistochemistry
  • Integrin alpha3beta1
  • Lymph Nodes
  • Middle Aged
  • Prognosis
  • Receptor, ErbB-2
  • Tetraspanin 24
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma : opposing roles of CD151 in invasive lobular and ductal breast cancers. / Romanska, Hanna M; Potemski, Piotr; Krakowska, Magdalena; Mieszkowska, Magdalena; Chaudhri, Shalini; Kordek, Radzisław; Kubiak, Robert; Speirs, Valerie; Hanby, Andrew M; Sadej, Rafał; Berditchevski, Fedor.

In: British Journal of Cancer, Vol. 113, No. 9, 03.11.2015, p. 1350-1357.

Research output: Contribution to journalArticle

Romanska, HM, Potemski, P, Krakowska, M, Mieszkowska, M, Chaudhri, S, Kordek, R, Kubiak, R, Speirs, V, Hanby, AM, Sadej, R & Berditchevski, F 2015, 'Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers', British Journal of Cancer, vol. 113, no. 9, pp. 1350-1357. https://doi.org/10.1038/bjc.2015.344
Romanska, Hanna M ; Potemski, Piotr ; Krakowska, Magdalena ; Mieszkowska, Magdalena ; Chaudhri, Shalini ; Kordek, Radzisław ; Kubiak, Robert ; Speirs, Valerie ; Hanby, Andrew M ; Sadej, Rafał ; Berditchevski, Fedor. / Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma : opposing roles of CD151 in invasive lobular and ductal breast cancers. In: British Journal of Cancer. 2015 ; Vol. 113, No. 9. pp. 1350-1357.
@article{a6a39b2d3913466fa05f2b06b80acb98,
title = "Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers",
abstract = "BACKGROUND: The proposed involvement of CD151 in breast cancer (BCa) progression is based on findings from studies in invasive ductal carcinoma (IDC). The IDC and invasive lobular carcinoma (ILC) represent distinct disease entities. Here we evaluated clinical significance of CD151 alone and in association with integrin α3β1 in patients with ILC in context of the data of our recent IDC study.METHODS: Expression of CD151 and/or integrin α3β1 was evaluated in ILC samples (N=117) using immunohistochemistry. The findings were analysed in relation to our results from an IDC cohort (N=182) demonstrating a prognostic value of an expression of CD151/integrin α3β1 complex in patients with HER2-negative tumours.RESULTS: Unlike in the IDCs, neither CD151 nor CD151/α3β1 complex showed any correlation with any of the ILC characteristics. Lack of both CD151 and α3β1 was significantly correlated with poor survival (P=0.034) in lymph node-negative ILC N(-) cases. The CD151(-)/α3β1(-) patients had 3.12-fold higher risk of death from BCa in comparison with the rest of the ILC N(-) patients.CONCLUSIONS: Biological role of CD151/α3β1 varies between ILC and IDC. Assessment of CD151/α3β1 might help to identify ILC N(-) patients with increased risk of distant metastases.",
keywords = "Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Female, Humans, Immunohistochemistry, Integrin alpha3beta1, Lymph Nodes, Middle Aged, Prognosis, Receptor, ErbB-2, Tetraspanin 24, Journal Article, Research Support, Non-U.S. Gov't",
author = "Romanska, {Hanna M} and Piotr Potemski and Magdalena Krakowska and Magdalena Mieszkowska and Shalini Chaudhri and Radzisław Kordek and Robert Kubiak and Valerie Speirs and Hanby, {Andrew M} and Rafał Sadej and Fedor Berditchevski",
year = "2015",
month = "11",
day = "3",
doi = "10.1038/bjc.2015.344",
language = "English",
volume = "113",
pages = "1350--1357",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma

T2 - opposing roles of CD151 in invasive lobular and ductal breast cancers

AU - Romanska, Hanna M

AU - Potemski, Piotr

AU - Krakowska, Magdalena

AU - Mieszkowska, Magdalena

AU - Chaudhri, Shalini

AU - Kordek, Radzisław

AU - Kubiak, Robert

AU - Speirs, Valerie

AU - Hanby, Andrew M

AU - Sadej, Rafał

AU - Berditchevski, Fedor

PY - 2015/11/3

Y1 - 2015/11/3

N2 - BACKGROUND: The proposed involvement of CD151 in breast cancer (BCa) progression is based on findings from studies in invasive ductal carcinoma (IDC). The IDC and invasive lobular carcinoma (ILC) represent distinct disease entities. Here we evaluated clinical significance of CD151 alone and in association with integrin α3β1 in patients with ILC in context of the data of our recent IDC study.METHODS: Expression of CD151 and/or integrin α3β1 was evaluated in ILC samples (N=117) using immunohistochemistry. The findings were analysed in relation to our results from an IDC cohort (N=182) demonstrating a prognostic value of an expression of CD151/integrin α3β1 complex in patients with HER2-negative tumours.RESULTS: Unlike in the IDCs, neither CD151 nor CD151/α3β1 complex showed any correlation with any of the ILC characteristics. Lack of both CD151 and α3β1 was significantly correlated with poor survival (P=0.034) in lymph node-negative ILC N(-) cases. The CD151(-)/α3β1(-) patients had 3.12-fold higher risk of death from BCa in comparison with the rest of the ILC N(-) patients.CONCLUSIONS: Biological role of CD151/α3β1 varies between ILC and IDC. Assessment of CD151/α3β1 might help to identify ILC N(-) patients with increased risk of distant metastases.

AB - BACKGROUND: The proposed involvement of CD151 in breast cancer (BCa) progression is based on findings from studies in invasive ductal carcinoma (IDC). The IDC and invasive lobular carcinoma (ILC) represent distinct disease entities. Here we evaluated clinical significance of CD151 alone and in association with integrin α3β1 in patients with ILC in context of the data of our recent IDC study.METHODS: Expression of CD151 and/or integrin α3β1 was evaluated in ILC samples (N=117) using immunohistochemistry. The findings were analysed in relation to our results from an IDC cohort (N=182) demonstrating a prognostic value of an expression of CD151/integrin α3β1 complex in patients with HER2-negative tumours.RESULTS: Unlike in the IDCs, neither CD151 nor CD151/α3β1 complex showed any correlation with any of the ILC characteristics. Lack of both CD151 and α3β1 was significantly correlated with poor survival (P=0.034) in lymph node-negative ILC N(-) cases. The CD151(-)/α3β1(-) patients had 3.12-fold higher risk of death from BCa in comparison with the rest of the ILC N(-) patients.CONCLUSIONS: Biological role of CD151/α3β1 varies between ILC and IDC. Assessment of CD151/α3β1 might help to identify ILC N(-) patients with increased risk of distant metastases.

KW - Breast Neoplasms

KW - Carcinoma, Ductal, Breast

KW - Carcinoma, Lobular

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Integrin alpha3beta1

KW - Lymph Nodes

KW - Middle Aged

KW - Prognosis

KW - Receptor, ErbB-2

KW - Tetraspanin 24

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/bjc.2015.344

DO - 10.1038/bjc.2015.344

M3 - Article

C2 - 26418423

VL - 113

SP - 1350

EP - 1357

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -